Quantcast

Latest Biosimilar Stories

2014-07-09 08:28:06

REDWOOD CITY, Calif., July 9, 2014 /PRNewswire/ -- Coherus BioSciences, Inc. ("Coherus"), announced today the appointment of V. Bryan Lawlis, Jr., Ph.D., former President and CEO of Itero Biopharmaceuticals, to its Board of Directors. "It is a privilege to join this talented Board of Directors, and I am excited about the opportunity to work with the Board and management to make Coherus the leader in the emerging business of biosimilars," Dr. Lawlis stated. "I look forward to working...

2014-07-08 23:08:23

ReportsnReports.com adds “PharmaSphere: Regulatory Frameworks and Product Pipelines in the Global Biosimilars Market” to its store. Lucrative Biosimilars Space to Erode Biologics Market from 2019. Dallas, Texas (PRWEB) July 08, 2014 The increasing prevalence of biosimilars will have a noticeably negative impact on the biologics market beyond 2019, despite an initial projected Compound Annual Growth Rate (CAGR) of 8.3%, taking the overall biologics market value from $162 billion in...

2014-07-01 12:28:22

LAKE FOREST, Ill., July 1, 2014 /PRNewswire/ -- Hospira, Inc. (NYSE: HSP), the world's leading provider of injectable drugs and infusion technologies, will host a conference call to discuss its second-quarter 2014 results on Wednesday, July 30, 2014 at 8 a.m. Central time. The company will release its second-quarter results earlier that morning, before the U.S. stock market open and the conference call. A live webcast of the conference call and related material will be available...

2014-06-30 23:11:03

ReportsnReports.com offers Human Insulin Market by Product Type (Human Insulin (Short Acting, Intermediate Acting, Premixed), Modern Human Insulin (Rapid Acting, Long Acting, Premixed), by Brand (Lantus, Apidra, Levemir, NovoRapid, Novomix, Tresiba, Others) - Forecast to 2018 research report in its store. This report is spread across 250 pages and provides 112 data tables as well as 43 figures to support the business intelligence and global human insulin market information provided in the...

2014-06-27 12:26:19

DALLAS, June 27, 2014 /PRNewswire/ -- According to the new market research report, "Human Insulin Market by Product Type (Human Insulin (Short Acting, Intermediate Acting, Premixed), Modern Human Insulin (Rapid Acting, Long Acting, Premixed), by Brand (Lantus, Apidra, Levemir, NovoRapid, Novomix, Tresiba, Others) - Forecast to 2018" published by MarketsandMarkets, The global Human Insulin Market crossed $23 Billion in 2013 and is poised to grow at a high double-digit CAGR from...

2014-06-23 12:29:24

Coherus Advances Development as Part of Collaboration with Daiichi Sankyo and Baxter REDWOOD CITY, Calif., June 23, 2014 /PRNewswire/ -- Coherus BioSciences, Inc. announced the start of its Phase 3 trial of CHS-0214, an investigational etanercept biosimilar, in rheumatoid arthritis (RA). The Phase 3 trial is a randomized, double-blind, active-control, parallel-group, multicenter, global study in subjects with active RA who have demonstrated an inadequate response to methotrexate....

2014-06-20 23:00:51

Industry experts Kevin Nelson and Dr. Patrick Gallagher from Duane Morris LLP will use examples from leading companies that are currently attempting to demonstrate biosimilarity. In this session, attendees will learn the specifics of the FDA’s newest recommendations for showing that a proposed product is “highly similar” to a reference product, gain fuller understanding of the impact of the just-released clinical guidance, and get newly-updated ideas and strategies based on the...

2014-06-19 23:01:46

Protecting consumers requires the ability to track products. Washington, DC (PRWEB) June 19, 2014 “The promise of personalized medicine will only be achieved when adequate information is available to clinicians to tailor care to the individual and ensure the best health outcomes for all,” said Jane L. Delgado, President and CEO of the National Alliance for Hispanic Health (the Alliance). Citing the “historic and continuing underrepresentation of minorities in clinical trials,” the...

2014-06-19 16:25:50

HSINCHU, Taiwan, June 19, 2014 /PRNewswire/ -- JHL Biotech, Inc., an emerging biopharmaceutical company, today announced that it has closed a Series B financing round of $35 million, led by new investors Milestone Capital and a consortium of Taiwan venture capitalists and individuals, including President International Development Corp., Fubon Financial Holdings, Taishin Financial Holdings, TaiAn Technologies, Hotung Group, Dr. Allen Chao (founder of Watson Pharmaceuticals), and...

2014-06-19 08:29:24

DUBLIN, June 19, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) today confirmed that the United States District Court for the District of Delaware has found certain claims of United States Patent Nos. 6,335,031 and 6,316,023 valid and infringed by Actavis' generic version of Novartis' Exelon(®) Patch (rivastigmine transdermal system). Actavis is reviewing the court's decision and will evaluate all available options, including an appeal. Exelon(®) Patch is a prescription medicine...


Word of the Day
drawcansir
  • A blustering, bullying fellow; a pot-valiant braggart; a bully.
This word is named for Draw-Can-Sir, a character in George Villiers' 17th century play The Rehearsal.
Related